CN101883564B - 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法 - Google Patents

使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法 Download PDF

Info

Publication number
CN101883564B
CN101883564B CN200880118761XA CN200880118761A CN101883564B CN 101883564 B CN101883564 B CN 101883564B CN 200880118761X A CN200880118761X A CN 200880118761XA CN 200880118761 A CN200880118761 A CN 200880118761A CN 101883564 B CN101883564 B CN 101883564B
Authority
CN
China
Prior art keywords
nilvadipine
treatment
composition
enantiomerically enriched
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880118761XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101883564A (zh
Inventor
M·J·穆兰
D·帕里斯
R·A·艾维三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roskamp Research LLC
Original Assignee
Roskamp Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roskamp Research LLC filed Critical Roskamp Research LLC
Publication of CN101883564A publication Critical patent/CN101883564A/zh
Application granted granted Critical
Publication of CN101883564B publication Critical patent/CN101883564B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN200880118761XA 2007-10-05 2008-10-03 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法 Expired - Fee Related CN101883564B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97795307P 2007-10-05 2007-10-05
US60/977,953 2007-10-05
US4610908P 2008-04-18 2008-04-18
US61/046,109 2008-04-18
PCT/US2008/078786 WO2009046323A1 (en) 2007-10-05 2008-10-03 Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Publications (2)

Publication Number Publication Date
CN101883564A CN101883564A (zh) 2010-11-10
CN101883564B true CN101883564B (zh) 2013-10-16

Family

ID=40523447

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880118761XA Expired - Fee Related CN101883564B (zh) 2007-10-05 2008-10-03 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法

Country Status (16)

Country Link
US (2) US8236346B2 (enExample)
EP (1) EP2214666B1 (enExample)
JP (1) JP5411145B2 (enExample)
KR (1) KR101417200B1 (enExample)
CN (1) CN101883564B (enExample)
AU (1) AU2008308519B2 (enExample)
BR (1) BRPI0817516A2 (enExample)
CA (1) CA2701620C (enExample)
DK (1) DK2214666T3 (enExample)
ES (1) ES2449594T3 (enExample)
MX (1) MX2010003669A (enExample)
NZ (1) NZ584729A (enExample)
PL (1) PL2214666T3 (enExample)
RU (1) RU2490014C2 (enExample)
TW (1) TWI500422B (enExample)
WO (1) WO2009046323A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140286910A1 (en) * 2013-03-19 2014-09-25 Nikolai Tankovich Stem cells and methods incorporating environmental factors as a means for enhancing stem cell proliferation and plasticity
CN112826794B (zh) 2019-11-06 2022-02-11 上海交通大学医学院 一种靶向修复神经血管病变的纳米复合物及其制备与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508413A (en) * 1987-08-27 1996-04-16 Fujisawa Pharmaceutical Co., Ltd. (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338322A (en) 1975-07-02 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same
JPS6038322A (ja) 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS61129140A (ja) 1984-11-27 1986-06-17 Nitto Electric Ind Co Ltd 医薬組成物
GB8431119D0 (en) 1984-12-10 1985-01-16 Fujisawa Pharmaceutical Co Anti-arteriosclerotic composition
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
ES2043719T3 (es) 1987-06-12 1994-01-01 American Cyanamid Co Administracion de farmacos por via percutanea.
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US4820720A (en) 1987-08-24 1989-04-11 Alza Corporation Transdermal drug composition with dual permeation enhancers
ES2037179T3 (es) 1987-11-25 1993-06-16 American Cyanamid Company Sistema de liberacion sostenida (controlada) para bloqueadores de canales de calcio de dihidropiridina.
US5160734A (en) 1987-11-25 1992-11-03 American Cyanamid Company Sustained release delivery system for substituted dihydropyridine calcium channel blockers
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2718105B2 (ja) 1988-10-27 1998-02-25 藤沢薬品工業株式会社 （＋）−２−シアノ−６−メチル−４−（３−ニトロフェニル）−１，４−ジヒドロピリジン−３，５−ジカルボン酸５−イソプロピル３−メチルの光安定性結晶
WO1990011761A1 (en) 1989-03-31 1990-10-18 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
JPH0381262A (ja) 1989-08-23 1991-04-05 Yamanouchi Pharmaceut Co Ltd ジヒドロピリジン系カルシウム拮抗薬の光学活性体の製造法
JP2867462B2 (ja) 1989-09-12 1999-03-08 藤沢薬品工業株式会社 経皮吸収用製剤
JP2920956B2 (ja) 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
US5258393A (en) 1990-02-21 1993-11-02 Fujisawa Pharmaceutical Co., Ltd. Use of a dihydropyridine compound for improving inner ear microcirculation
EP0557290A1 (en) 1990-08-23 1993-09-01 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
WO1993005770A1 (fr) 1991-09-20 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Preparation a longue duree d'action
JPH05139974A (ja) 1991-11-26 1993-06-08 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固体分散体の製造法
US5834496A (en) 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
DE4141646A1 (de) 1991-12-17 1993-06-24 Klinge Co Chem Pharm Fab Arzneimittelkombination mit synergistischer wirkung, verfahren zu seiner herstellung und seine verwendung
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4229805A1 (de) 1992-09-07 1994-03-24 Werner E G Prof Dr Mueller Kalzium-Kanal-Antagonisten oder deren Derivate zur Herstellung eines Arzneimittels zur Bekämpfung von Erkrankungen, die durch Prion-Proteine oder Prion-analoge Proteine ausgelöst werden
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
AU682192B2 (en) * 1993-06-30 1997-09-25 Fujisawa Pharmaceutical Co., Ltd. Encapsulated medicine
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JP3541389B2 (ja) 1996-04-26 2004-07-07 藤沢薬品工業株式会社 ジヒドロピリジン化合物を含有する眼組織末梢循環改善剤
US6271259B1 (en) 1996-05-07 2001-08-07 Ito En, Ltd. Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death
KR100222306B1 (ko) 1996-11-20 1999-10-01 이병언 닐바디핀 속효성 고형제제 및 이의 제조방법
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
CA2318806A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding agents that modulate the 5-ht transporter
JP2002517440A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド 新規カルシウムチャンネル薬物および用途
RU2243768C2 (ru) 1998-07-10 2005-01-10 Новартис Аг Гипотензивная комбинация валсартана и блокатора кальциевых каналов
WO2001064250A1 (en) 2000-03-03 2001-09-07 Fujisawa Pharmaceutical Co., Ltd. Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof
WO2001076598A1 (en) 2000-04-11 2001-10-18 Sankyo Company, Limited Stabilized pharmaceutical compositions containing calcium channel blockers
JP2001335483A (ja) 2000-05-30 2001-12-04 Nichiko Pharmaceutical Co Ltd ニルバジピン含有製剤
CA2415826A1 (en) 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
JP3968687B2 (ja) 2000-09-13 2007-08-29 東和薬品株式会社 易吸収性ニルバジピン錠
JP3470096B2 (ja) 2000-09-19 2003-11-25 沢井製薬株式会社 ニルバジピン含有易溶性固形製剤およびその製造法
JP2004516269A (ja) 2000-12-19 2004-06-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング チエノピリミジンおよび抗血栓剤、カルシウム拮抗剤、プロスタグランジンまたはプロスタグランジン誘導体を含有する医薬製剤
BR0115995A (pt) 2000-12-19 2004-01-13 Merck Patent Gmbh Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
US7083642B2 (en) 2000-12-22 2006-08-01 Avantec Vascular Corporation Delivery of therapeutic capable agents
CA2333494A1 (en) 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
MXPA03010843A (es) 2001-05-25 2004-02-17 Schering Corp Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer.
EP1426051B1 (en) 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
PL219032B1 (pl) 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AR040017A1 (es) 2002-05-17 2005-03-09 Novartis Ag Combinacion de compuestos organicos
JP2003146878A (ja) 2002-11-22 2003-05-21 Sawai Pharmaceutical Co Ltd ニルバジピン含有易溶性固形製剤およびその製造法
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2006512417A (ja) 2002-12-24 2006-04-13 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
ES2334029T3 (es) * 2003-05-15 2010-03-04 Roskamp Research Llc Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis.
JP2004002460A (ja) 2003-07-29 2004-01-08 Towa Yakuhin Kk 易吸収性ニルバジピン錠の製造法
WO2009046338A1 (en) * 2007-10-05 2009-04-09 Roskamp Research Llc Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508413A (en) * 1987-08-27 1996-04-16 Fujisawa Pharmaceutical Co., Ltd. (+)-5-isopropyl 3-methyl 2-cyano-6 methyl-4-(3-nitrophenyl)-1, 4-dihydropyridine-3, 5-dicarboxylate

Also Published As

Publication number Publication date
KR20100067683A (ko) 2010-06-21
US8236346B2 (en) 2012-08-07
US8236347B2 (en) 2012-08-07
EP2214666B1 (en) 2013-12-11
AU2008308519A1 (en) 2009-04-09
TWI500422B (zh) 2015-09-21
TW200920364A (en) 2009-05-16
MX2010003669A (es) 2010-11-25
JP2010540661A (ja) 2010-12-24
WO2009046323A1 (en) 2009-04-09
CA2701620A1 (en) 2009-04-09
CA2701620C (en) 2014-12-09
KR101417200B1 (ko) 2014-08-01
BRPI0817516A2 (pt) 2015-06-16
RU2010117634A (ru) 2011-11-10
PL2214666T3 (pl) 2014-06-30
AU2008308519A2 (en) 2010-04-29
EP2214666A4 (en) 2010-12-08
CN101883564A (zh) 2010-11-10
US20090092667A1 (en) 2009-04-09
ES2449594T3 (es) 2014-03-20
JP5411145B2 (ja) 2014-02-12
AU2008308519B2 (en) 2014-09-11
NZ584729A (en) 2012-12-21
DK2214666T3 (da) 2014-01-27
RU2490014C2 (ru) 2013-08-20
EP2214666A1 (en) 2010-08-11
US20100183711A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
Bachurin et al. Drugs in clinical trials for Alzheimer's disease: the major trends
KR101660401B1 (ko) 신생혈관형성증 조절을 통한 알츠하이머 질환 및 관련 장애의 치료를 위한 신규 치료학적 접근법
JP2021006552A (ja) アルツハイマー病と関連疾患の治療のための併用療法
US6660725B1 (en) Method and composition for modulating amyloidosis
US8455504B2 (en) Inhibition of the activity of the capsaicin receptor in the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance or insulin resistance
JP2012526844A5 (enExample)
JP2012526844A (ja) Ｍｃｉおよびアルツハイマー病の処置
BR112021001272A2 (pt) métodos de tratamento e prevenção de doença de alzheimer
JP2013526518A (ja) Ｍｃｉおよびアルツハイマー病の処置
CN101883564B (zh) 使用(-)-尼伐地平对映体减少淀粉状蛋白沉积、淀粉状蛋白神经毒性和小神经胶质增生的方法
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
CN109789129B (zh) 自噬改良材料及其用途
US20100093810A1 (en) Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
US20240115581A1 (en) Combination therapy for the treatment or prevention of neurological disorders
Bakar A pharmacovigilance study on Memantine: signal detection of Rhabdomyolysis and death
WO2024061474A1 (en) Combination therapy for the treatment or prevention of neurological disorders
Trevisani et al. Vanilloid (TRPV1) and other transient receptor potential channels
BR122025003268A2 (pt) Métodos de tratamento e prevenção de doença de alzheimer
Cardinali et al. Cytoprotective Role of Sleep

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131016

Termination date: 20211003

CF01 Termination of patent right due to non-payment of annual fee